Antisense oligonucleotides: Modifications and clinical trials

MedChemComm

Volumn 5, Issue 10, 2014, Pages 1454-1471

  Sharma, Vivek K ^a   Sharma, Raman K ^b   Singh, Sunil K ^c  

^a UNIVERSITY OF DELHI   (India)

^b Evalueserve Pvt Ltd   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 35156; AGANIRSEN; AGATOLIMOD; ALICAFORSEN; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APRINOCARSEN; APTAMER; AVI 4126; BEVASIRANIB; CENERSEN; CUSTIRSEN; DEFIBROTIDE; DNA; DRISAPERSEN; EDIFOLIGIDE; ETEPLIRSEN; FOMIVIRSEN; GATAPARSEN; GTI 2040; MIPOMERSEN; MIRAVIRSEN; NUCLEIC ACID BASE; OBLIMERSEN; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PEGAPTANIB; RIBOZYME; RNA; TRABEDERSEN; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; AGE RELATED MACULAR DEGENERATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTISENSE THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; B CELL LYMPHOMA; BREAST CANCER; CHEMICAL MODIFICATION; CHRONIC LYMPHATIC LEUKEMIA; CORNEA NEOVASCULARIZATION; CROHN DISEASE; CYTOMEGALOVIRUS RETINITIS; DIET THERAPY; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; DUCHENNE MUSCULAR DYSTROPHY; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; GLIOBLASTOMA; HEPATITIS C; HUMAN; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MELANOMA; MULTIPLE MYELOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; PROSTATE CANCER; RESTENOSIS; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SOLID TUMOR;

EID: 84907811492     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c4md00184b     Document Type: Review

References (163)

1. Y. Guan C. Hao D. R. Cha R. Rao W. Lu D. E. Kohan M. A. Magnuson R. Redha Y. Zhang M. D. Breyer Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption Nat. Med. 2005 11 861 866
2. H. Zhang A. Zhang D. E. Kohan R. D. Nelson F. J. Gonzalez T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor (γ) blocks thiazolidinedione-induced fuid retention Proc. Natl. Acad. Sci. U. S. A. 2005 102 9406 9411
3. B. M. Paterson B. E. Roberts E. L. Kuff Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation Proc. Natl. Acad. Sci. U. S. A. 1977 74 4370 4374
4. P. C. Zamecnik M. L. Stephenson Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide Proc. Natl. Acad. Sci. U. S. A. 1978 75 280 284
5. S. R. Zheng G. L. Guo Q. Zhai Z. Y. Zou W. Zhang Effects of miR-155 antisense oligonucleotide on breast carcinoma cell line MDA-MB-157 and implanted tumors Asian Pac. J. Cancer Prev. 2013 14 2361 2366
6. J. Besseling G. K. Hovingh E. S. Stroes Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises Neth. J. Med. 2013 71 118 122
7. C. Carrieri L. Cimatti M. Biagioli A. Beugnet S. Zucchelli S. Fedele E. Pesce I. Ferrer L. Collavin C. Santoro A. R. Forrest P. Carninci S. Biffo E. Stupka S. Gustincich Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat Nature 2012 491 454 457
8. C. F. Bennett E. E. Swayze RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu. Rev. Pharmacol. Toxicol. 2010 50 259 293
9. E. Uhlmann A. Peyman Antisense oligonucleotides: a new therapeutic principle Chem. Rev. 1990 90 543 584
10. J. Micklefield Backbone modification of nucleic acids: synthesis, structure and therapeutic applications Curr. Med. Chem. 2001 8 1157 1179
11. TLDNA): Design, synthesis, and double-strand formation with natural DNA Org. Lett. 2008 10 3729 3732
12. A. Lauristen J. Wengel Oligodeoxynucleotides containing amide-linked LNA-type dinucleotides: synthesis and high-affinity nucleic acid hybridisation Chem. Commun. 2002 530 531
13. J. Zang J. T. Shaw M. D. Matteucci Synthesis and hybridisation property of an oligonucleotide containing a 3′-thioformacetal linked pentathymidylate Bioorg. Med. Chem. Lett. 1999 9 319 322
14. A. Waldner A. D. Mesmaker Synthesis of oligodeoxyribonucleotides containing dimmers with carbamate moieties as replacement of the natural phosphodiester linkage Bioorg. Med. Chem. Lett. 1994 4 405 408
15. V. K. Sharma S. K. Singh K. Bohra L. Chandrashekhar V. Khatri C. E. Olsen A. K. Prasad Design and synthesis of LNA-based mercaptoacetamido-linked nucleoside dimmers Nucleosides, Nucleotides Nucleic Acids 2013 32 256 272
16. B. Bhat E. E. Swayze P. Wheeler S. Dimock M. Perbost Y. S. Sanghvi Synthesis of novel nucleic acid mimics via the stereoselective intermolecular radical coupling of 3′-iodo nucleosides and formaldoximes(1) J. Org. Chem. 1996 61 8186 8199
17. K. Gogoi A. D. Gunjal U. D. Phalgune V. A. Kumar Synthesis and RNA binding selectivity of oligonucleotides modified with five-atom thioacetamido nucleic acid backbone structures Org. Lett. 2007 9 2697 2700
18. M. S. Frier K. H. Altmann The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA: RNA duplexes Nucleic Acids Res. 1997 25 4429 4443
19. P. S. Pallan P. Matt C. J. Wilds K. H. Altmann M. Egli RNA-Binding affinities and crystal structure of oligonucleotides containing five-atom amide-based backbone structures Biochemistry 2006 45 8048 8057
20. A. De Mesmaeker C. Lesueur M.-O. Bèvierre V. Fritsch R. M. Wolf Amide backbones with conformationally restricted furanose rings: highly improved affinity of the modified oligonucleotides for their RNA complements Angew. Chem., Int. Ed. Engl. 1996 35 2790 2794
21. X. Xie J. Liang T. Pu F. Xu F. Yao Y. Yang Y. L. Zhao D. You X. Zhou Z. Deng Z. Wang Phosphorothioate DNA as an antioxidant in bacteria Nucleic Acids Res. 2012 40 9115 9124
22. S. M. Rahman T. Baba T. Kodama M. A. Islam S. Obika Hybridising ability and nuclease resistance profile of backbone modified cationic phosphorothioate oligonucleotides Bioorg. Med. Chem. 2012 20 4098 4102
23. E. DeClerq F. Eckstein T. C. Merigan Interferon induction increased through chemical modification of a synthetic polyribonucleotide Science 1969 165 1137 1139
24. S. T. Crooke, Phosphorothioate oligonucleotides, in Therapeutic Applications of Oligonucleotides, ed., S. T. Crooke, Austin RG Landes, 1995, pp. 63-79
25. J. E. Coughlin R. K. Pandey S. Padmanabhan K. G. O'Loughlin J. Marquis C. E. Green J. C. Mirsalis R. P. Iyer Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate Drug Metab. Dispos. 2012 40 970 981
26. G. B. Mulamba A. Hu R. F. Azad K. P. Anderson D. M. Coen Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide Fomivirsen (ISIS 2922) Antimicrob. Agents Chemother. 1998 42 971 973
27. T. P. Prakash An overview of sugar-modified oligonucleotides from antisense therapeutics Chem. Biodiversity 2011 8 1616 1641
28. T. P. Prakash B. Bhat 2′-Modified oligonucleotides for antisense therapeutics Curr. Top. Med. Chem. 2007 7 641 649
29. S. Obika K. Morio D. Nanbu Y. Hari H. Itoh T. Imanishi Synthesis and conformation of 3′,4′-BNA monomers, 3′-O,4′-C-methyleneribonucleosides Tetrahedron 2002 58 3039 3049
30. 3, -endo sugar puckering Tetrahedron Lett. 1997 38 8735 8738
31. A. A. Koshkin J. Fensholdt H. M. Pfundheller C. J. Lomholt A simplified and efficient route to 2′-O,4′-C-methylene-linked bicyclic ribonucleosides J. Org. Chem. 2001 66 8504 8512
32. J. K. Watts Locked nucleic acid: tighter is different Chem. Commun. 2013 49 5618 5620
33. S. Obika J. Andoh T. Sugimoto K. Miyashita T. Imanishi Synthesis of a conformationally locked AZT analogue, 3′-azido-3′-deoxy-2′-O,4′-C-mthylene-5-methyluridine Tetrahedron Lett. 1999 40 6465 6468
34. R. Steffens C. J. Leumann Synthesis and thermodynamic and biophysical properties of tricycle-DNA J. Am. Chem. Soc. 1999 121 3249 3255
35. B. De Bouvere L. Kerreinans C. Hendrix H. De Winter G. Schepers A. Van Aerschot P. Herdewijn Hexitol nucleic acids (HNA): synthesis and properties Nucleosides Nucleotides 1997 16 973 976
36. M. T. Migawa T. P. Prakash G. Vasquez P. P. Seth E. E. Swayze Synthesis and biophysical properties of constrained D-altritol nucleic acids (cANA) Org. Lett. 2013 15 4316 4319
37. J. Wang B. Verbeure I. Luyten M. Froeyen C. Hendrix H. Rosemeyer F. Seela A. Van Aerschot P. Herdewijn Cyclohexene nucleic acids (CeNA) form stable duplexes with RNA and induce RNase H activity Nucleosides, Nucleotides Nucleic Acids 2001 20 785 788
38. D. Sabatino M. J. Damha Oxepane nucleic acids: synthesis, characterisation, and properties of oligonucleotides bearing a seven-membered carbohydrate ring J. Am. Chem. Soc. 2007 129 8259 8270
39. Y. Yoshimura B. A. Otter T. Ueda A. Matsuda Nucleosides and nucleotides. 108. Synthesis and optical properties of syn-fixed carbon-bridged pyrimidine cyclonucleosides Chem. Pharm. Bull. 1992 40 1761 1769
40. B. Ravindra Babu L. Keinicke J. Wengel Synthesis of 2′-spiro ribo- and aribonucleosides. Nucleoside Nucleosides, Nucleotides Nucleic Acids 2003 22 1313 1315
41. M. J. Camarasa M. J. Pérez-Pérez A. San-Félix J. Balzarini E. De Clercq 3′-Spironucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and ribofuranose]-3′-spiro-5′′[4′′-amino-1′′,2′′-oxathiole 2′′,2′′-dioxide] (TSAO) pyrimidine nucleosides J. Med. Chem. 1992 35 2721 2727
42. L. A. Paquette Spirocyclic restriction of nucleosides Aust. J. Chem. 2004 57 7 17
43. W. Guschlbauer K. Jankowski Nucleoside conformation is determined by the electronegativity of the sugar substituent Nucleic Acids Res. 1980 8 1421 1433
44. W. Saenger, Principles of nucleic acid structures, Springer-Verlag, New York, 1984, p. 556
45. T. P. Prakash B. Bhat 2′-Modified oligonucleotides for antisense therapeutics Curr. Top. Med. Chem. 2007 7 641 649
46. V. K. Sharma R. Kumar P. Rungta V. S. Parmar A. K. Prasad Modified oligonucleotides: strides towards antisense drugs Trends Carbohydr. Res. 2013 3 1 7
47. E. W. Ng D. T. Shima P. Calias E. T. Cunningham Jr D. R. Guyer A. P. Adamis Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat. Rev. Drug Discovery 2006 5 123 132
48. L. C. Griffin G. F. Tidmarsh L. C. Bock J. J. Toole L. L. Leung In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits Blood 1993 81 3271 3276
49. Y. Kasahara S. Kitadume K. Morihiro M. Kuwahara H. Ozaki H. Sawai T. Imanishi S. Obika Effect of 3′-end capping of aptamer with various 2′,4′-bridged nucleotides: Enzymatic post-modification toward a practical use of polyclonal aptamers Bioorg. Med. Chem. Lett. 2010 20 1626 1629
50. L. Beigelman J. Matulic-Adamic P. Haeberli N. Usman B. Dong R. H. Silverman S. Khamnei P. F. Torrence Synthesis and biological activities of a phosphorodithioate analog of 2′,5′-oligoadenylate Nucleic Acids Res. 1995 23 3989 3994
51. A. D. Keefe S. Pai A. Ellington Aptamers as therapeutics Nat. Rev. Drug Discovery 2010 9 537 550
52. T. Aboul-Fadl Antisense oligonucleotides: the state of the art Curr. Med. Chem. 2005 12 2193 2214
53. P. Herdewijn Heterocyclic modifications of oligonucleotide and antisense technology Antisense Nucleic Acid Drug Dev. 2000 10 297 310
54. H. Peacock A. Kannan P. A. Beal C. J. Burrows Chemical modification of siRNA bases to probe and enhance RNA interference J. Org. Chem. 2011 76 7295 7300
55. S. Verma F. Eckstein Modified oligonucleotides: synthesis and strategy for users Annu. Rev. Biochem. 1998 67 99 134
56. O. Seitz Chemically modified antisense oligonucleotides: recent improvements of RNA binding and ribonuclease H recruitment Angew. Chem., Int. Ed. 1999 38 3466 3469
57. K. Y. Lin M. D. Matteucci A cytosine analogue capable of clamp-like binding to a guanine in helical nucleic acids J. Am. Chem. Soc. 1998 120 8531 8532
58. K. Y. Lin R. J. Jones M. Matteucci Tricyclic 2′-deoxycytidine analogs: synthesis and incorporation into oligodeoxynucleotides which have enhanced binding to complementary RNA J. Am. Chem. Soc. 1995 117 3873 3874
59. B. S. Sproat A. I. Lamond B. Beijer P. Neuner U. Ryder Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases Nucleic Acids Res. 1989 17 3373 3386
60. P. P. Seth A. Jazayeri J. Yu C. R. Allerson B. Bhat E. E. Swayze Structure activity relationships of α-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals Mol. Ther.-Nucleic Acids 2012 1 e47
61. B. P. Monia E. A. Lesnik C. Gonzalez W. F. Lima D. McGee C. J. Guinosso A. M. Kawasaki P. D. Cook S. M. Freier Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitore of gene expression J. Biol. Chem. 1993 268 14514 14522
62. M. P. McGowan J. Tardif R. Ceska L. J. Burgess H. Soran I. Gouni-Berthold G. Wagener S. Chasan-Taber Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS One 2012 7 e49006
63. http://www.isispharm.com/About-Isis/KYNAMRO.htm
64. M. E. Gleave B. P. Monia Antisense therapy for cancer Nat. Rev. Cancer 2005 5 468 479
65. P. E. Nielsen M. Egholm R. H. Berg O. Buchardt Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide Science 1991 254 1497 1500
66. 3′-endo-puckered pyrrolidine containing PNA has favourable geometry for RNA binding: Novel ethano locked PNA (ethano-PNA) Bioorg. Med. Chem. 2013 21 4092 4101
67. P. E. Nielsen PNA technology Mol. Biotechnol. 2004 26 233 248
68. F. J. Schnell S. L. Crumley D. V. Mourich P. L. Iversen Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissues and cells BioRes. Open Access 2013 2 61 66
69. A. Amantana P. L. Iversen Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers Curr. Opin. Pharmacol. 2005 5 550 555
70. M. H. Nelson D. A. Stein A. D. Kroeker S. A. Hatlevig P. L. Iversen H. M. Moulton Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity Bioconjugate Chem. 2005 16 959 966
71. A. P. McCaffrey L. Meuse M. Karimi C. H. Contag M. A. Kay A potent and specific morpholino antisense inhibitor of heptatis C translation in mice Hepatology 2003 38 503 508
72. P. L. Iversen T. K. Warren J. B. Wells N. L. Garza D. V. Mourich L. S. Welch R. G. Panchal S. Bavari Discovery and early development of AVI-7537 and AVI-7288 for the treatment of ebola virus and Marburg virus infections Viruses 2012 4 2806 2830
73. C. M. Perry J. A. Balfour Fomivirsen Drugs 1995 57 375 380
74. P. Hair F. Cameron K. McKeage Mipomersen sodium: first global approval Drugs 2013 73 487 493
75. E. E. Akar V. Oner C. Küçükerdönmez Y. Aydin Akova Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularisation in a rat model Int. J. Ophthalmol. 2013 6 136 140
76. J. C. Burnett J. J. Rossi RNA-based therapeutics: current progress and future prospects Chem. Biol. 2012 19 60 71
77. G. Borthakur S. O'Brien Pharmocology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia Blood Lymphatic Cancer 2012 2 137 143
78. F. Jaschinski T. Rothhammer P. Jachimczak C. Seitz A. Schneider K. H. Schlingensiepen The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2 Curr. Pharm. Biotechnol. 2011 12 2203 2213
79. C. Cursiefen F. Bock F. K. Horn F. E. Kruse B. Seitz V. Borderie B. Früh M. A. Thiel F. Wilhelm B. Geudelin I. Descohand K. P. Steuhl A. Hahn D. Meller GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularisation: interim results of a randomized phase II trial Ophthalmology 2009 116 1630 1637
80. S. A. Grossman J. B. Alavi J. G. Supko K. A. Carson R. Priet F. A. Dorr J. S. Grundy J. T. Holmlund Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-α delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas Neuro-Oncology 2005 7 32
81. J. J. Laskin G. Nicholas C. Lee B. Gitlitz M. Vincent Y. Cormier J. Stephenson Y. Ung R. Sanborn B. Pressnail F. Nugent J. Nemunaitis M. E. Gleave N. Murray D. Hao Phase I/II trial of custirsen (OGX-011), an inhibitor of custirsen, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer J. Thorac. Oncol. 2012 7 579 5586
82. http://clinicaltrials.gov/ct2/results?term=GSK-2402968
83. L. Singerman Combination therapy using the small interfering RNA bevasiranib Retina 2009 29 S49 S50
84. http://www.gentium.com/products/defibrotide
85. P. G. Richardson R. J. Soiffer J. H. Antin H. Uno Z. Jin J. Kurtzberg P. L. Martin G. Steinbach K. F. Murray G. B. Vogelsang A. R. Chen A. Krishnan N. A. Kernan D. E. Avigan T. R. Spitzer H. M. Shulman D. N. Di Salvo C. Revta D. Warren P. Momtaz G. Bradwin L. J. Wei M. Iacobelli G. B. McDonald E. C. Guinan Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial Biol. Blood Marrow Transplant. 2007 16 1005 1017
86. Y. H. Kim M. Girardi M. Duvic T. Kuzel B. K. Link L. Pinter-Brown A. H. Rook Phase I trail of a Toll like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma J. Am. Acad. Dermatol. 2010 63 975 983
87. Y. M. Murad T. M. Clay H. K. Lyerly M. A. Morse CPG-7909 (PF-3512676, ProMune): Toll-like receptor-9 agonist in cancer therapy Expert Opin. Biol. Ther. 2007 7 1257 1266
88. http://www.im.org/AcademicAffairs/Aging/IGP/Expanding ResearchEfforts/Documents/1CPG%207909.pdf
89. M. Barry C. Cooper Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy Expert Opin. Biol. Ther. 2007 7 1731 1737
90. B. Yacyshyn W. Y. Chey M. K. Wedel R. Z. Yu D. Paul E. Chuang A randomized, double-masked, placebo-controlled study of alicaforsen, and antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's deisease Clin. Gastroenterol. Hepatol. 2007 5 215 220
91. H. S. Sekhon C. A. London M. Sekhon P. L. Iversen G. R. Devi c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastatis in a murine tumor model Lung Cancer 2008 60 347 354
92. http://investorrelations.avibio.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=928275&highlight=
93. http://www.drugfuture.com/chemdata/edifoligide-sodium.html
94. A. W. Hoel M. S. Conte Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass Cardiovasc. Drug Rev. 2007 25 221 234
95. S. Callies V. André B. Patel D. Waters P. Francis M. Burgess M. Lahn Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide Br. J. Clin. Pharmacol. 2011 71 416 428
96. http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle-pf&ID=1290230&highlight
97. V. Malik L. Rodino-Klapac V. Mendell Jr Emerging drugs for Duchenne muscular dystrophy Expert Opin. Emerging Drugs 2012 17 261 277
98. D. S. Hong R. Kurzrock Y. Oh J. Wheler A. Naing L. Brail S. Callies V. André S. K. Kadam A. Nasir T. R. Holzer F. Meric-Bernstam M. Fishman G. Simon A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer Clin. Cancer Res. 2011 17 6582 6591
99. http://www.biotechnologyevents.com/node/6313
100. Y. Ando T. Coelho J. L. Berk M. W. Cruz B. Ericzon S. Ikeda W. D. Lewis L. Obici V. Planté-Bordeneuve C. Rapezzi G. Said F. S. Orphanet Guideline of transthyretin-related hereditary amyloidosis for clinicians J. Rare Dis. 2013 8 31
101. M. Lindow S. Kauppinen Discovering the first microRNA-targeted drug J. Cell Biol. 2012 199 407 412
102. J. K. Watts D. R. Corey Clinical status of suplex RNA Bioorg. Med. Chem. Lett. 2010 20 3203 3207
103. J. Cortes H. Kantarjian E. D. Ball J. Dipersio J. E. Kolitz H. F. Fernandez M. Goodman G. Borthakur M. R. Baer M. Wetzler Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia Cancer 2012 118 418 427
104. A. Siedlecki W. Irish D. C. Brennan Delayed graft function in the kidney transplant Am. J. Transplant. 2011 11 2279 2296
105. P. Chen J. Aimiuwu Z. Xie X. Wei S. Liu R. Klisovic G. Marcucci K. K. Chan Biochemical modulation of Aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells AAPS J. 2011 13 131 140
106. http://www.rexahn.com/cms/index.php/2012/08/rexahn-pharmaceuticals-announces-positive-top-line-phase-iia-data-for-archexin-in-patients-with-metastatic-pancreatic-cancer/
107. M. E. Wechsler P. C. Fulkerson B. S. Bochner G. M. Gauvreau G. J. Gleich T. Henkel R. Kolbeck S. K. Mathur H. Ortega J. Patel C. Prussin P. Renzi M. E. Rothenberg F. Roufosse D. Simon H. Simon A. Wardlaw P. F. Weller A. D. Klion Novel targeted therapies for eosinophilic disorders J. Allergy Clin. Immunol. 2012 130 563 571
108. J. Cummings T. H. Ward E. LaCasse C. Lefebvre M. St-Jean J. Durkin M. Ranson C. Dive Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP Br. J. Cancer 2005 92 532 538
109. http://www.tevapharm.com/Media/News/Pages/2008/1554740.aspx
110. J. DeVincenzo J. E. Cehelsky R. Alvarez S. Elbashir J. Harborth I. Toudjarska L. Nechev V. Murugaiah A. Van Vliet A. K. Vaishnaw R. Meyers Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV) Antiviral Res. 2008 77 225 231
111. Q. D. Nguyen R. A. Schachar C. I. Nduaka M. Sperling A. S. Basile K. J. Klamerus K. Chi-Burris E. Yan D. A. Paggiarino I. Rosenblatt R. Aitchison S. S. Erlich Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study) Invest. Ophthalmol. Visual Sci. 2012 53 7666 7674
112. P. Fidias N. A. Pennell A. L. Boral G. I. Shapiro A. T. Skarin J. P. Eder Jr T. J. Kwoh R. S. Geary B. E. Johnson T. J. Lynch J. G. Supko Phse I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and palcitaxel in patients with previously untreated, advanced non-small cell lung cancer J. Thorac. Oncol. 2009 4 1156 1162
113. C. M. Rudin J. Holmlund G. F. Fleming S. Mani W. M. Stadler P. Schumm B. P. Monia J. F. Johnston R. Geary R. Z. Yu T. J. Kwoh F. A. Dorr M. J. Ratain Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer Clin. Cancer Res. 2001 7 1214 1312
114. J. G. McHutchison K. Patel P. Pockros L. Nyberg S. Pianko R. Z. Yu F. A. Dorr T. J. Kwoh A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients J. Hepatol. 2006 44 88 96
115. S. Goel K. Desai M. Macapinlac S. Wadler G. Goldberg A. Fields M. Einstein F. Volterra B. Wong R. Martin S. Mani A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers Invest. New Drugs 2006 24 125 134
116. Y. Lee A. Vassilakos N. Feng H. Jin M. Wang K. Xiong J. Wright A. Young GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors Int. J. Oncol. 2006 28 469 478
117. http://www.antisense.com.au/product-pipeline/atl1103-for-growth-sight-disorders/
118. A. Hosseini F. A. Lattanzio Jr S. S. Samudre G. DiSandro J. D. Sheppard Jr P. B. Williams Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model J. Ocul. Pharmacol. Ther. 2012 28 194 201
119. J. D. Sussman Z. Argov D. McKee E. Hazum S. Brawer H. Soreq Antisense treatment for myasthenia gravis: experience with monarsen Ann. N. Y. Acad. Sci. 2008 1132 283 290
120. P. Brown-Augsburger X. M. Yue J. A. Lockridge J. A. McSwiggen D. Kamboj K. M. Hillgren Determination of Glycosides and sugars in Moutan Cortex by capillary electrophoresis with electrochemical detection J. Pharm. Biomed. Anal. 2004 34 129 134
121. A. A. Adjei G. K. Dy C. Erlichman J. M. Reid J. A. Sloan H. C. Pitot S. R. Alberts R. M. Goldberg L. J. Hanson P. J. Atherton T. Watanabe R. S. Geary J. Holmlund F. A. Dorr A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with Gemcitabine in patients with advanced cancer Clin. Cancer Res. 2003 9 115 123
122. S. T. Crooke Potential roles of antisense technology in cancer chemotherapy Oncogene 2000 19 6651 6659
123. J. L. Johnson W. Guo J. Zang S. Khan S. Bardin A. Ahmad J. X. Duggan I. Ahmad Quantification of raf antisense oligonucleotide (rafAON) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulation Biomed. Chromatogr. 2005 19 272 278
124. R. Plummer L. Vidal M. Griffin M. Lesley J. de Bono S. Coulthard J. Sludden L. L. Siu E. X. Chen A. M. Oza G. K. Reid A. R. McLeod J. M. Besterman C. Lee I. Judson H. Calvert A. V. Boddy Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors Clin. Cancer Res. 2009 15 3177 3183
125. R. J. Amato Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy Clin. Genitourin. Cancer 2007 5 422 426
126. http://www.taisho.co.jp/en/company/release/2000/022900-e.htm
127. R. Zheng Technology evaluation: GEM-92, hybridon inc Curr. Opin. Mol. Ther. 1999 1 521 523
128. http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&id=1531705
129. V. Baylot C. Andrieu M. Katsogiannou D. Taieb S. Garcia S. Giusiano J. Acunzo J. Iovanna M. Gleave C. Garrido P. Rocchi OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cell Cell Death Dis. 2011 2 e221
130. S. P. Henry M. Johnson T. A. Zanardi R. Fey D. Auyeung P. B. Lappin A. A. Levin Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey Toxicology 2012 301 13 20
131. P. Hnik D. S. Boyer L. R. Grillone J. G. Clement S. P. Henry E. A. Green Antisense oligonucleotide therapy in diabetic retinopathy J. Diabetes Sci. Technol. 2009 3 924 930
132. N. M. Dean, J. G. Foulkes, G. Hardee, M. Jewell, L. Krochmal, N. O'Donnell and L. Young, US pat., 2012/0238937 A1
133. J. Dürig U. Dührsen L. Klein-Hitpass J. Worm J. B. Hansen H. Ørum M. Wissenbach The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia Leukemia 2011 25 638 647
134. M. Chasen S. Z. Hirschman R. Bhargava Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia J. Am. Med. Dir. Assoc. 2011 12 62 67
135. http://www.ohrpharmaceutical.com
136. P. Jilma-Stohlawetz P. Knöbl J. C. Gilbert B. Jilma The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease Thromb. Haemostasis 2012 108 284 290
137. B. Cosmi ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent Curr. Opin. Mol. Ther. 2009 11 322 328
138. http://ichgcp.net/clinical-trialsregistry/research/index/NCT00381433
139. V. Arora M. L. Cate C. Ghosh P. L. Iversen Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism Drug Metab. Dispos. 2002 30 757 762
140. http://www.enzo.com/therapeutics/stealth-vector-hgtv43.asp
141. I. Mender S. Senturk N. Ozgunes K. C. Akcali D. Kletsas S. Gryaznov A. Can J. W. Shay Z. G. Dikmen Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton Int. J. Oncol. 2013 42 1709 1715
142. S. Agrawal E. R. Kandimalla Synthetic agonists of Toll-like receptors 7, 8 and 9 Biochem. Soc. Trans. 2007 35 1461 1467
143. Z. Makowska T. Blumer F. H. Duong N. La Monica E. R. Kandimalla M. H. Heim Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist J. Hepatol. 2013 58 743 749
144. D. Trabattoni A. Clivio D. H. Bray L. Bhagat S. Beltrami G. Maffeis E. Cesana P. Lowry F. Lissoni E. R. Kandimalla T. Sullivan S. Agrawal R. Bartholomew M. Clerici Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice Vaccine 2006 24 1470 1477
145. K. L. Sewell R. S. Geary B. F. Baker J. M. Glover T. G. Mant R. Z. Yu J. A. Tami F. A. Dorr Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha J. Pharmacol. Exp. Ther. 2002 303 1334 1343
146. http://www.mesorfa.org/treatments/veglin.php
147. P. K. Kaiser R. C. Symons S. M. Shah E. J. Quinlan H. Tabandeh D. V. Do G. Reisen J. A. Lockridge B. Short R. Guerciolini Q. D. Nguyen RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027 Am. J. Ophthalmol. 2010 150 33 39
148. http://www.antisense.com.au/product-pipeline/atl1101-for-prostate-cancer/
149. L. M. Greenberger I. D. Horak D. Filpula P. Sapra M. Westergaard H. F. Frydenlund C. Albaek H. Schrøder H. Ørum A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth Mol. Cancer Ther. 2008 7 3598 3608
150. http://ichgcp.net/clinical-trials-registry/research/index/NCT00387283
151. P. Sapra M. Wang R. Bandaru H. Zhao L. M. Greenberger I. D. Horak Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide Nucleosides, Nucleotides Nucleic Acids 2010 29 97 112
152. http://www.alnylam.com/Programs-and-Pipeline/Partner-Programs/Liver-Cancer.php
153. A. C. Eifler C. S. Thaxton Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study Methods Mol. Biol. 2011 726 325 338
154. http://materials.proxyvote.com/Approved/464330/20090406/AR-39097/PDF/isis-pharmaceuticals-ar2008-0014.pdf
155. T. A. Zanardi S. C. Han E. J. Jeong S. Rime R. Z. Yu K. Chakravarty S. P. Henry Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2 J. Pharmacol. Exp. Ther. 2012 342 489 496
156. A. I. So R. J. Levitt B. Eigl L. Fazli M. Muramaki S. Leung M. C. Cheang T. O. Nielsen M. Gleave M. Pollak Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer Clin. Cancer Res. 2008 14 6944 6954
157. http://www.cancer.gov/drugdictionary?cdrid=43388
158. F. P. S. Santos, I. Hazan-Halevy and Z. Estrov, Targeting signal transducer and activator of transcription (STAT) for anticancer therapy, in Cell Signaling & Molecular Targets in Cancer, ed., Chatterjee M, and, Kashfi K, Springer, 2012, pp. 299-321
159. M. C. Catley Asthma and COPD-IQPC's second conference IDrugs 2010 13 601 604
160. http://www.tekmira.com/pipeline/tkm-plk1.php
161. http://clinicaltrials.gov/ct2/show/NCT02065336
162. V. K. Sharma P. Rungta A. K. Prasad Nucleic acid therapeutics: basic concepts and recent developments RSC Adv. 2014 4 16618 16631
163. Data retrieved from http://www.clinicaltrials.gov/ and respective companies websites